立方制药(003020.SZ)：前三季度净利润1.21亿元 同比增加1.65%

Core Viewpoint - Lifan Pharmaceutical (003020.SZ) reported a decline in revenue for the first three quarters of 2025, while net profit showed a slight increase, indicating mixed financial performance [1] Financial Performance - The company achieved an operating revenue of 1.081 billion yuan, a year-on-year decrease of 3.95% [1] - The net profit attributable to shareholders of the listed company was 121 million yuan, reflecting a year-on-year increase of 1.65% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 89.35 million yuan, which represents a year-on-year decrease of 20.23% [1] - Basic earnings per share stood at 0.64 yuan [1]